Content Type: Article

  • IRS Proposes Section 163(j) Regulations – New Business Interest Expenses Deduction Limit

    IRS Proposes Section 163(j) Regulations – New Business Interest Expenses Deduction Limit

    ARTICLE / CLIENT ALERT

    IRS Proposes Section 163(j) Regulations – New Business Interest Expenses Deduction Limit

    December 21, 2018

    Read time: 4 min

    Key takeaways
    Overview
    In depth

    On November 26, 2018, the Internal Revenue Service (IRS) issued proposed regulations (Proposed Regulations) pursuant to section 163(j). Public Law 115-97, the Tax Cuts and Jobs Act (TCJA), amended Internal Revenue Code (Code) Section 163 by modifying paragraph (j) to limit the amount of business interest a taxpayer may deduct for taxable years beginning after December 31, 2017. The amendment generally limits the deduction for business interest to the sum of a taxpayer’s business interest income and thirty percent of a taxpayer’s adjusted taxable income (ATI) for the taxable year.

    The Code Section 163(j) limit is also increased by a taxpayer’s “floor plan financing interest,” which is certain interest used to finance the acquisition of motor vehicles held for sale or lease. Code Section 163(j)(8) defines ATI as a taxpayer’s taxable income computed without regard to: any item of income, gain, deduction, or loss which is not properly allocable to a trade or business; any business interest or business interest income; any net operating loss deduction under Code Section 172; the amount of any deduction for qualified business income under Code Section 199A; and in the case of taxable years beginning before January 1, 2022, any deduction allowable for depreciation, amortization, or depletion.

    The Proposed Regulations address a variety of issues, including the following:

    • Trade or Business. New Code Section 163(j) defines business interest income and expense as amounts that are “properly allocable to a trade or business,” but it does not define trade or business.” The Proposed Regulations define a “trade or business” by reference to Code Section 162 because Code Section 162(a) provides the “most established and developed definition of trade or business.”
    • Interest. The Proposed Regulations define “interest” broadly to include other ordinary income items similar to interest, such as substitute interest payments in securities lending transactions, loan commitment fees, debt issuance costs, Code Section 707(c) guaranteed payments for the use of capital, and factoring income. Proposed Regulation § 1.163(j)-3 introduces rules, including ordering rules, for the relationship between Code Section 163(j) and other provisions affecting interest.
    • S Corporations. Proposed Regulation § 1.163(j)-6 provides guidance regarding the application of the Code Section 163(j) deduction to partnerships and S corporations.
    • CFCs. The Proposed Regulations provide that Code Section 163(j) may apply to limit the deductibility of a controlled foreign corporation’s (CFC’s) business interest expense, thereby potentially limiting a CFC’s deduction of business interest for purposes of computing subpart F income and tested income under Code Section 951A(c)(2)(A).
    • ECI. The Proposed Regulations also provide that Code Section 163(j) applies to foreign corporations and other foreign persons for purposes of computing income effectively connected with a US trade or business.

    The Proposed Regulations provide a variety of other rules. Some of the notable provisions include rules applicable to REITs, RICs, tax-exempt entities and consolidated group members. They also provide rules regarding the disallowed business interest expense carryforwards of C corporations and rules regarding elections for excepted trades or businesses and rules for allocating expenses and income between non-excepted and excepted trades or businesses.

    Practice Point: With the amendment of Code Section 163(j), the ability of some taxpayers to deduct interest on intercompany debt has been diminished substantially. This may require a taxpayer to reevaluate funding and capital structures, and may necessitate a new strategy.

    Authors

    David D. Sherwood

    Counsel

    Washington, DC

    More insights

  • A Few GILTI Planning Tips

    ARTICLE

    A Few GILTI Planning Tips

    November / December 2018

    Read time: 2 min

    Key takeaways
    Overview

    Lowell Yoder authored this bylined article discussing how to minimize US taxation of income earned by a controlled foreign corporation.

    In depth
    Authors

    Lowell D. Yoder

    Partner

    Chicago

    More insights

  • OCR Requests Information from Stakeholders on Significant Changes to the HIPAA Rules

    OCR Requests Information from Stakeholders on Significant Changes to the HIPAA Rules

    ARTICLE / CLIENT ALERT

    OCR Requests Information from Stakeholders on Significant Changes to the HIPAA Rules

    December 20, 2018

    Read time: 17 min

    Key takeaways
    Overview

    The US Department of Health and Human Services, Office for Civil Rights (OCR) published a long-awaited Request for Information seeking feedback on whether and how the HIPAA Rules should be revised to better promote coordinated care. While some of the proposals on which OCR is seeking feedback might potentially reduce burden on Covered Entities, others could result in new requirements that Covered Entities would need to invest time and resources in implementing in their HIPAA compliance programs.

    In depth

    On December 14, 2018, the US Department of Health and Human Services, Office for Civil Rights (OCR) published a long-awaited Request for Information (RFI) that seeks feedback on whether and how the HIPAA Privacy and Security Rules (HIPAA Rules) should be revised to better promote coordinated care. In a press release, OCR indicated that its primary goal in issuing the RFI is to identify whether certain HIPAA provisions unnecessarily “limit or discourage information sharing needed for coordinated care or to facilitate the transformation to value-based health care.” The RFI is broad in scope and suggests that OCR is considering making the first significant changes to the HIPAA Rules since its January 2013 HIPAA Omnibus Rulemaking. Stakeholders have until February 12, 2019 to submit comments to OCR electronically through www.regulations.gov or by mail.

    OCR specifically requests stakeholders to comment on the following proposals for potential modifications to the HIPAA Rules:

    1. Create an express requirement for Covered Entities to timely respond to requests for protected health information (PHI) from other Covered Entities (and non-covered health care providers) for the purposes of treatment, payment and health care operations, including care coordination and case management
    2. Except disclosures of PHI to Covered Entities and non-covered health care providers for care coordination and case management from the HIPAA Privacy Rule’s minimum necessary standard
    3. Establish an express regulatory permission for Covered Entities to disclose PHI to social service agencies or community-based support programs
    4. No longer consider health care clearinghouses as Business Associates of Covered Entity health care providers when processing claims and/or require health care clearinghouses to be directly subject to requirements to provide individuals with access to PHI
    5. Establish new permissions for Covered Entities to disclose PHI to family members, caregivers, and others in a position to avert threats of harm to health and safety, or when necessary to promote the health and recovery of individuals with substance use disorders or serious mental illness, as well as reduce potential barriers to caregiver involvement in individuals’ health care that are presented by the “personal representative” concept under the HIPAA Privacy Rule
    6. Implement the HITECH Act’s mandate to expand the HIPAA Privacy Rule’s accounting of disclosures requirement to include disclosures through an Electronic Health Record (EHR) over the previous three years for treatment, payment and health care operations (and withdraw OCR’s May 2011 Notice of Proposed Rulemaking, in which OCR proposed to establish a new patient right to an “access report” listing each time the individual’s information in an electronic designated record set was accessed for either a “use” or a “disclosure”)
    7. Establish a safe harbor for Covered Entities that use OCR’s Model Notice of Privacy Practices and eliminate or modify the obligation for covered health care providers with direct treatment relationships with individuals to make a good faith effort to obtain a written acknowledgment of an individual’s receipt of the provider’s Notice of Privacy Practices

    We provide more details below regarding the foregoing proposed modifications to the HIPAA Rules and the significance of OCR’s corresponding requests for information.

    Requiring Covered Entities to Timely Disclose PHI to Other Covered Entities and Health Care Providers for Treatment, Payment, and Health Care Operations Purposes

    The HIPAA Privacy Rule currently permits Covered Entities to disclose PHI to other Covered Entities and non-covered health care providers without individual authorization for certain treatment, payment and health care operations purposes. OCR is considering amending the HIPAA Rules to generally require—and not merely permit—Covered Entities to disclose PHI to other Covered Entities (and non-covered health care providers) upon receiving a request for access to PHI from such providers for treatment purposes. To that end, OCR solicits public comment on whether such a requirement would effectively reduce any barriers health care providers experience when seeking to obtain medical records or other forms of PHI directly from Covered Entities for treatment purposes. In addition, OCR requests comment on whether Covered Entities should also be required to disclose PHI to requesting Covered Entities or non-covered health care providers for the purposes of payment and health care operations, including care coordination and case management.

    OCR seemingly recognizes that the contemplated mandatory disclosure requirement would have sweeping implications for both HIPAA-regulated entities and health care consumers, and the agency seeks input on whether it should narrow the scope of any such requirement. With consumers’ privacy interests in mind, OCR raises the possibility of limiting any mandatory disclosure requirement in the following ways:

    • Applying the requirement to only a subset of Covered Entities
    • Applying the requirement only to disclosures between Covered Entities, rather than disclosures from Covered Entities to health care providers who are not also covered by HIPAA
    • Limiting the requirement to only certain categories of disclosures (for example, only treatment and payment disclosures)
    • Limiting the requirement to only certain categories of PHI (for example, PHI maintained in a designated record set) or excepting specific types of PHI from the requirement (such as psychotherapy notes)
    • Allowing an individual to “opt-out” of certain categories of required disclosures (such as disclosures for health care operations purposes)
    • Requiring a Covered Entity to obtain the individual’s authorization before requesting PHI for an acceptable purpose from another Covered Entity

    OCR also requests feedback on whether any more restrictive state or federal laws or regulations, including the Confidentiality of Substance Use Disorder Patient Records regulations (42 C.F.R. Part 2), would limit the potential application of the suggested mandatory disclosure requirement.

    Relatedly, OCR seeks comment on whether it should impose a timeliness requirement for any mandatory disclosures from a Covered Entity to a requesting Covered Entity or non-covered health care provider. OCR requests input on whether certain categories of disclosures (such as treatment disclosures) should be subject to stricter deadlines than other ones. Further, OCR is considering whether PHI stored in particular media formats, such as electronic records, should be furnished to the requesting entity more rapidly than PHI in other forms, such as paper. OCR also appears to be simultaneously exploring whether the HIPAA Privacy Rule’s access provisions should be modified to incorporate stricter timeliness requirements for responding to individuals’ requests to access certain types of PHI, such as electronic PHI.

    An update to the HIPAA Privacy Rule that imposes a mandatory disclosure requirement is likely to impact the daily operations of both Covered Entities and non-covered health care providers alike. Covered Entities, health care providers, and other interested stakeholders should consider sending OCR comments that weigh the potential benefits and costs of such a requirement.

    Eliminating the Minimum Necessary Requirement for Care Coordination and Case Management Disclosures

    Generally, the HIPAA Privacy Rule requires a Covered Entity to reasonably limit its uses and disclosures of PHI to the minimum amount of PHI necessary to achieve the intended purpose of the use or disclosure. The minimum necessary standard, however, does not apply to disclosures that a Covered Entity makes to a health care provider for treatment purposes.

    OCR solicits comment on whether the minimum necessary standard should continue to apply to disclosures made by Covered Entities for certain health care operations purposes. Specifically, OCR requests public input on whether the exceptions to the minimum necessary standard should also include “population-based case management and care coordination activities, claims management, review of health care services for appropriateness of care, utilization reviews, or formulary development.” OCR is also interested in identifying other potential exceptions to the minimum necessary standard that would promote the goals of care coordination and case management.

    Covered Entities that participate in an organized health care arrangement (OHCA) or other clinically integrated settings that are not commonly owned or controlled should consider submitting comments to OCR on this topic. Because these Covered Entities share PHI with one another for joint health care operations activities, they are especially likely to benefit from the suggested additional exceptions to the HIPAA Privacy Rule’s minimum necessary standard.

    Disclosures of PHI to Social Service Agencies or Community-Based Support Programs

    Currently, the HIPAA Privacy Rule permits Covered Entities to disclose PHI to social service agencies or community-based support programs (Agencies and Programs) for treatment purposes, which includes the coordination or management of health care by a health care provider with a third party. OCR recognizes, however, that Covered Entities are nonetheless currently hesitant to share PHI with these Agencies and Programs without a written authorization or Business Associate Agreement (BAA) because these recipients are not directly subject to HIPAA.

    OCR is exploring whether to amend the HIPAA Privacy Rule to more explicitly permit such disclosures without authorization or a BAA or, alternatively, require these Agencies and Programs to agree to protect PHI in a similar manner to a Business Associate before the Covered Entity can disclose PHI to them.

    A more explicit HIPAA pathway for disclosures between Covered Entities and Agencies and Programs may facilitate treatment disclosures in instances where Covered Entities are currently hesitant to share PHI without a written authorization due to the recipient Agency or Program not being a Covered Entity or Business Associate under HIPAA. In other instances, however, requiring Covered Entity health care providers and Agencies and Programs to enter into agreements similar to BAAs could create additional burdens for the Agencies and Programs, as well as the Covered Entity health care providers that refer patients to them. The RFI discusses situations where multidisciplinary teams could include law enforcement officials, such as drug courts, and suggests that an alternative process may be needed to account for the presence of law enforcement officials. But 42 C.F.R. Part 2 typically dictates the procedure for disclosing PHI to and from drug court multidisciplinary teams because 42 C.F.R. Part 2 contains more stringent protections than HIPAA. Creating a BAA-like pathway for disclosures between drug courts and Covered Entities could potentially require drug court teams (e.g., judges, court staff and social workers) to both obtain 42 C.F.R. Part 2-compliant consents and enter into an agreement with special HIPAA-compliant terms with the Covered Entities.

    Covered Entity health care providers that currently use the existing treatment pathway to disclose PHI to Agencies and Programs should consider providing feedback to OCR on this proposal given the significant changes that OCR appears to be contemplating to these disclosures.

    Health Care Clearinghouses

    Under the current HIPAA Rules, health care clearinghouses are Covered Entities that function as Business Associates of Covered Entity health care providers when they assist them with engaging in standard transactions with health plans. Given the large volume of PHI held by a health care clearinghouse, OCR posits in the RFI that individuals could potentially access their full treatment histories from health care clearinghouses without having to separately request PHI from each of their health care providers. OCR further queries whether the status of a health care clearinghouse as a Business Associate, which is often subject to BAA provisions restricting its ability to respond directly to individuals’ access requests, may be a barrier to improving individuals’ ability to receive timely access to PHI.

    Accordingly, OCR is considering whether the health care clearinghouse should be directly subject to individual access requirements. OCR is also examining whether the health care clearinghouse should be solely classified as Covered Entities, eliminating the need for a BAA to be in place between the clearinghouse and Covered Entity health care providers. OCR recognizes potential concerns with the latter approach, particularly if Covered Entity health care providers would not be able to impose other contractual limitations on how health care clearinghouses can use and disclose PHI, such as by limiting clearinghouses’ uses and disclosures of PHI received from providers to those necessary to process claims.

    The majority of patients and beneficiaries may not be aware that a health care clearinghouse processes their data, let alone the particular clearinghouse from which they can request access to their PHI. Given the access fee limitations imposed by both the HIPAA Privacy Rule and certain state laws, it is unclear whether a health care clearinghouse would have financial or other incentives to advertise its PHI access fulfillment services to patients and other individuals. Classifying clearinghouses as Covered Entities may not be the only way to improve and facilitate patient access to PHI. Covered Entities (including health care clearinghouses), patients and their advocates, and other industry stakeholders should consider sending comments to OCR regarding the value of imposing access obligations on health care clearinghouses and the extent to which individuals’ access rights under the HIPAA Privacy Rule would be enhanced.

    Family Members, Caregivers, and Others’ Role in Promoting the Health and Recovery of Individuals with Substance Use Disorders or Serious Mental Illness

    The HIPAA Privacy Rule generally permits Covered Entity health care providers to share an individual’s PHI with family members, friends and caregivers, so long as the individual has been given the opportunity to object to the disclosure when feasible. Covered Entities are also allowed to disclose PHI to prevent or lessen a serious and imminent threat to an individual’s safety (including to the individual’s family members, friends, caregivers and others in a position to alleviate the threat). In October 2017, OCR issued guidance clarifying when HIPAA permits Covered Entities to discuss an individual’s PHI with his or her family, friends and others during crisis situations, such as the opioid crisis. Later that year, OCR issued guidance regarding when HIPAA permits Covered Entities to share mental health information with third parties.

    In the RFI, OCR acknowledges that misunderstandings continue to persist around when HIPAA allows Covered Entities to share PHI with an individual’s caregivers and other third parties. Such confusion, OCR finds, “may hinder effective coordination of care and case management involving caregivers, including family and friends.” Consequently, OCR states that it will consider issuing a separate rulemaking to encourage Covered Entities to disclose PHI to an individual’s family members, caregivers and others, as needed to prevent harm to a person’s health or safety, assist those struggling with substance use disorder (such as opioid use disorder), and promote the health of those with serious mental illness.

    OCR also seeks comment on whether the HIPAA Rules frustrate the ability of parents and guardians to obtain critical information about their unemancipated minor children, including PHI about their mental health and substance use disorders. Similarly, OCR solicits feedback on whether the HIPAA Rules’ provisions permitting disclosures to an individual’s legal personal representative need to be amended to accommodate various treatment coordination scenarios, such as when adult children who need to readily access treatment information about their elderly parent for whom they are caregivers. OCR’s questions on this topic signal that the agency is seeking a solution that will balance the potential detriment to a patient’s health if a Covered Entity cannot easily share PHI with his or her caregivers against the patient’s interests in privacy and autonomy.

    Accounting of Disclosures for Treatment, Payment and Health Care Operations

    Section 13405(c) of the HITECH Act dramatically expanded the original accounting of disclosures requirement to newly require the inclusion of very routine disclosures. Specifically, Congress directed OCR to promulgate regulations to give individuals the right to receive an accounting of treatment, payment and healthcare operations disclosures through an EHR for the previous three years, but only in a manner that balances the interests of individuals in learning the circumstances under which their PHI is being disclosed and the administrative burden of accounting for such disclosures.

    In May 2011, OCR released a Notice of Proposed Rulemaking that would have required Covered Entities that had implemented an EHR to make available to individuals, upon request, an “access report” detailing each access of PHI in the electronic designated record set made during a three-year period (whether the access resulted in a “use” or “disclosure” of PHI). OCR never finalized the rule due to significant negative feedback in public comments to the rulemaking, including concerns about the technological feasibility of producing an access report, the prohibitive cost of adding access report functionality, and the lack of information that would be meaningful or useful to individuals in an access report.

    The RFI announces OCR’s intention to withdraw the May 2011 proposed rule and seeks input on alternative approaches to making an accounting available that includes treatment, payment and health care operations disclosures. Specifically, OCR seeks granular information about the number of treatment, payment and health care operations disclosures made by Covered Entities and by Business Associates on their behalf and about the experience of Covered Entities with accounting of disclosures requests under current law, such as the frequency of such requests, the length of time needed to respond to such requests, and information about whether compiling an accounting is done manually and/or automatically through the EHR.

    While the RFI states that the access report requirement proposed in May 2011 would create “undue burden for covered entities without providing meaningful information to individuals,” OCR includes questions relating to the ability of EHRs to distinguish “uses” from “disclosures” and the type of information recorded for each access event. OCR seemingly seeks to confirm the technological infeasibility that commenters described in 2011.

    In other RFI questions, OCR requests comments on whether it would be sufficient for OCR to require Covered Entities to conduct and document “a diligent investigation into disclosures of PHI upon receiving an individual’s request for an accounting of disclosures” for treatment, payment and health care operations. OCR wonders whether this requirement could apply not just to disclosures made through EHRs, but disclosures made orally or using paper records as well.

    The ideas contemplated in the accounting of disclosures queries could create significant administrative and technological burdens for Covered Entities, and it will be important for Covered Entities to respond fully to these questions to convey the difficulties in developing these accountings. Indeed, throughout this RFI section on accountings, OCR seeks detailed information about current practices and technological capacity, as well as predictions about future capacity, including cost estimates of adding certain functionalities.

    Notice of Privacy Practices

    Currently, a Covered Entity health care provider is required to provide its Notice of Privacy Practices (NPP) to individuals by the date of first service delivery and upon an individual’s request. In addition, Covered Entity health care providers that have a direct treatment relationship with an individual must make a good faith effort to obtain a written acknowledgment that the individual has received the health care provider’s NPP. OCR is seeking input on whether to eliminate the written acknowledgment requirement and is requesting specifics on the administrative burdens currently created by the requirement. Covered Entity health care providers would likely welcome the elimination of the NPP acknowledgment requirement because it would remove a recordkeeping requirement that arguably does not lead to more patients reading the NPP itself.

    OCR is also considering creating a safe harbor that would deem Covered Entity health care providers in compliance with the HIPAA Privacy Rule’s NPP requirement if they implement one of OCR’s model NPPs, which are available on OCR’s website. These model notices, which are more concise and easier to read than the typical NPP, may become more widely adopted if OCR elects to provide a compliance safe harbor for their use.

    Conclusion

    Overall, OCR appears to be signaling significant rulemaking in 2019 relating to HIPAA. While some of the proposals discussed above might potentially reduce burden on Covered Entities, others could result in new requirements that Covered Entities would need to invest time and resources in addressing in their HIPAA compliance policies, procedures, and forms.

    The RFI provides Covered Entities, Business Associates and other stakeholders an important opportunity to express support of or opposition to these proposals before they are introduced in proposed rulemaking. In addition, HIPAA-regulated entities may want to consider putting forth additional ideas to assist OCR with reconciling HIPAA with current health care industry priorities, such as modernizing preparatory to research rules to keep pace with precision medicine, creating enforcement safe harbors for certain types of cyber-attacks, and facilitating data-sharing between health plans and providers engaging in value-based pricing arrangements.

    Please contact your regular McDermott attorney or any of the authors of this On the Subject for more information on the RFI or if you are interested in assistance with drafting a responsive comment. McDermott is hosting a breakfast on January 17, 2019 in our Washington, DC. office, where we will discuss the RFI and reactions from industry stakeholders. To RSVP, please contact Jennifer Randles at jrandles@mcdermottplus.com.

    Authors

    Jennifer S. Geetter

    Partner

    Washington, DC

    Karen S. Sealander

    Counsel

    Washington, DC

    More insights

  • Proposed BEAT Regulations | Tax-Free Transactions May Give Rise to a Liability

    Proposed BEAT Regulations | Tax-Free Transactions May Give Rise to a Liability

    ARTICLE / CLIENT ALERT

    Proposed BEAT Regulations | Tax-Free Transactions May Give Rise to a Liability

    December 20, 2018

    Read time: 6 min

    Key takeaways
    Overview
    In depth

    On December 13, 2018, US Department of the Treasury and the Internal Revenue Service (IRS) released proposed regulations for the Base Erosion and Anti-Abuse Tax (the BEAT), which was added to the Code as part of the 2017 Tax Act. The proposed regulations provide helpful guidance on a range of important topics and generally go a long way toward a reasonable implementation of a very challenging statute. There is one aspect of the proposed regulations, however, that may be an unwelcome surprise for many taxpayers; the proposed regulations treat stock consideration in non-cash transactions as BEAT “payments,” thereby creating the potential for BEAT liability in situations involving certain liquidations, tax-free reorganizations and other non-cash transactions.

    Located in section 59A, the BEAT imposes a minimum tax on US corporations (and certain foreign corporations, which are not the focus of this Insight) that consistently have annual gross receipts of $500 million or more and claim more than a de minimis amount of “base erosion tax benefits” for a taxable year. In general, as base erosion tax benefits increase, a corporate taxpayer’s BEAT liability increases.

    The proposed regulations, which are generally proposed to be effective for tax years beginning after December 31, 2017, include guidance for determining the base erosion payments that will give rise to annual base erosion tax benefits. Prop. Reg. § 1.59A-3(b) applies the same four categories of base erosion payments found in section 59A(d) for amounts paid or accrued to a related foreign party. The two categories that should affect the most taxpayers are the general category for currently deductible items and the special category for the acquisition of depreciable or amortizable property. With respect to this latter category, the acquisition price of the property will constitute the base erosion payment, but only the amount of any depreciation or amortization deductions claimed in a tax year will produce a base erosion tax benefit for purposes of computing the BEAT.

    The proposed regulations adopt complex operating rules to implement various key concepts set forth in the Code. One notable operating rule is found in Prop. Reg. § 1.59A-3(b)(2), providing that a base erosion payment may consist of “any form of consideration” provided by a corporate taxpayer and includes “cash, property, stock, or the assumption of a liability.” The preamble to the proposed regulations notes this rule may capture otherwise innocuous inbound non-recognition transactions between members of a commonly controlled multinational group where the parties use non-cash consideration, such as stock. For purposes of this rule, the preamble specifically identifies sections 351 exchanges, section 332 liquidations and tax-free reorganizations described in section 368 as base erosion payments under the special category for the acquisition of depreciable or amortizable property.

    As a result, internal restructuring transactions such as inbound “A,” “C,” “D” and “F” asset reorganizations can give rise to base erosion payments notwithstanding the fact that such transactions are undertaken with a bona fide business purpose or otherwise comport with other policy objectives of the 2017 Tax Act, which encourage the on-shoring of income-producing assets. This may be seen as a harsh result given that US corporations can generally implement such transactions on a tax-free basis following the 2017 Tax Act.

    The amortization and depreciation of the assets acquired by a US corporation in such inbound transactions would be considered a base erosion tax benefit. Thus, while taxpayers generally prefer a fair market value basis step-up for acquired property, in the BEAT context, having a value-basis disparity with a lower carryover basis may be preferential in order to limit future base erosion tax benefits. Such a disparity may also enhance a corporate US corporation’s foreign-derived intangible income benefit under section 250 due to decreased basis in qualified business investment assets.

    The preamble confirms, however, that depreciable or amortizable property distributed to a US corporation by a foreign subsidiary in a section 301 distribution cannot give rise to base erosion tax benefits because the US corporation provided no consideration in exchange for the property.

    The proposed regulations do not elaborate further beyond what is described above, leaving several questions open. For example, should form or substance control for purposes of determining whether a US corporation makes a base erosion payment for depreciable or amortizable property? If substance controls, then the deemed issuance of stock under the meaningless gesture doctrine in a section 351 exchange or in a section 368 tax-free asset reorganization would constitute a base erosion payment even though no non-cash consideration is provided. Likewise, a deemed section 332 liquidation, as part of a check-the-box election, would also constitute a base erosion payment. Alternatively, if form controls, then dividend equivalent redemptions under section 302(d), which are treated as section 301 distributions, would constitute base erosion payments because the US corporation technically provides stock in consideration for the acquired property.

    The proposed regulations also provide helpful transition guidance for depreciable or amortizable property that was acquired from a foreign related party before the BEAT was enacted. Specifically, the preamble to the proposed regulations confirms that depreciation or amortization deductions taken in 2018 or beyond from property that was acquired before December 31, 2017, cannot give rise to a base erosion tax benefit, because the payment for the property was made prior to the effective date of the statute.

    In summary, although the proposed regulations provide helpful guidance on a range of different issues, if the new operating rules in the proposed regulations are finalized in their current form, US corporations could trigger a significant BEAT liability for internal, business-motivated transactions that are intended to be tax-free. A US corporation can avoid this result by causing any depreciable or amortizable property to be distributed as part of a section 301 distribution, which, depending on the circumstances, may or may not be completely tax-free following the 2017 Tax Act. Finally, any depreciation or amortization deductions claimed on property acquired before the BEAT was enacted should not give rise to a base erosion tax benefit and, thus, should be excluded from the BEAT computation.

    Authors

    David G. Noren

    Partner

    Washington, DC

    More insights

  • IP Update, Vol. 21, No. 12

    IP Update, Vol. 21, No. 12

    ARTICLE

    IP Update, Vol. 21, No. 12

    December 2018

    Read time: 1 min

    Key takeaways
    Overview

    Dive into the December 2018 issue of IP Update: Vol. 21, No. 12

    In depth
    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    Amol Parikh

    Partner

    Chicago

    More insights

  • Bioengineered Food Disclosures

    ARTICLE

    Bioengineered Food Disclosures

    November / December 2018

    Read time: 2 min

    Key takeaways
    Overview

    Vanessa Burrows authored this bylined article on the United States Department of Agriculture’s proposed regulation that would require food manufacturers to disclose information about bioengineered (BE) food and BE food ingredients.

    In depth
    Authors
    More insights

  • Updated Yates Memo Still Has Force In Civil Domain

    ARTICLE

    Updated Yates Memo Still Has Force In Civil Domain

    December 19, 2018

    Read time: 8 min

    Key takeaways
    Overview

    Sarah Walters and Rebecca Martin authored this bylined article on the Yates memo and the individual accountability in the context of corporate investigations.

    In depth

    In September 2015, Deputy Attorney General Sally Yates issued the Yates memo on individual accountability in the context of corporate investigations. It is no understatement to say that this memo created a near-cottage industry of articles and panels on the memo’s impact on government investigations and officer/director liability.

    After the change in administration, a favorite parlor game of the defense bar was wagering on the memo’s survival. And after Deputy Attorney General Rod Rosenstein revealed, in September and October 2017, that the Yates memo was under active reconsideration, discussions turned serious about whether the memo would be preserved, diluted or outright reversed and whether the distinctions between criminal and civil False Claims Act matters would receive needed nuance.

    Announcement of Significant Changes to Individual Accountability in Criminal and Civil Cases

    On Nov. 29, the deputy attorney general put an end to much speculation, announcing the much-awaited changes to U.S. Department of Justice policy on individual accountability in the corporate context. The Yates memo still lives, but is scaled back in the criminal context and further downsized in the context of civil (i.e., FCA) matters — in a manner that seems designed to lessen inefficiencies, but not in way that, on its face, eases the focus on senior management.

    As a starting point, the deputy attorney general emphasized that under the revised policy, “pursuing individuals responsible for wrongdoing” will continue to be “a top priority in every corporate investigation.” In the criminal context, the revised DOJ policy makes clear that “absent extraordinary circumstances, a corporate resolution should not protect individuals from criminal liability.”

    The revised policy, however, unquestionably reins in the level of disclosure previously required by the Yates memo. As then-Acting Associate Attorney General Bill Baer previously outlined in 2016, the DOJ expected companies to disclose “all facts relating to the individuals involved in the wrongdoing, no matter where those individuals fall in the corporate hierarchy in order to obtain cooperation credit in criminal matters under the Yates regime.” This concept may sound, on its face, straightforward, but implementation in the context of alleged culpable conduct spanning a long time period or involving routine corporate operations and hundreds of individuals has proven inefficient and problematic to expeditious resolutions — as the deputy attorney general explicitly acknowledged. To complicate matters further, the principles of the Yates memo were interpreted, and applied, inconsistently among districts even in the criminal context.

    Now, under the revised DOJ policy, companies under criminal investigation need “only” identify individuals who were “substantially involved” in the alleged conduct. Notably, however, in the context of Foreign Corrupt Practices Act matters, the Justice Manual still requires, “disclos[ing] … all relevant facts about all individuals involved in the violation of law” in order “to receive credit for voluntary self-disclosure of wrongdoing” and DOJ representatives have stated publicly that these same principles will be applied more generally in non-FCPA corporate cases as well.[1] How this tension with the revised criminal policy gets resolved is an open question. And while, overall, the revised policy should lift part of the burden of investigations, there is little doubt that the meaning of “substantially involved” will be fertile ground for dispute and if not managed with care, could create a minefield for defense counsel when identifying the appropriate individuals.

    Indeed, the deputy attorney general expressly noted, “If we find that a company is not operating in good faith to identify individuals who were substantially involved in or responsible for wrongdoing, we will not award any cooperation credit.” In a nod to these risks, the deputy attorney general encourages defense counsel to have “full and frank discussions with prosecutors about how to gather the relevant facts” — a practice that could mitigate a negative outcome. The new policy on cooperation in corporate criminal matters can be found in the updated Justice Manual.

    Civil Cases Are Different

    The deputy attorney general emphasized that principles of individual accountability continue to apply in the civil/FCA context, but was also clear that “civil cases are different.” Indeed, the primary focus of civil fraud investigations — as Rosenstein acknowledges — has always been the money, and although many districts historically focused on individual liability, the Yates-driven changes created inefficiency and needless delay in civil resolutions:

    The idea that a company that engaged in a pattern of wrongdoing should always be required to admit the civil liability of every individual employee as well as the company is attractive in theory, but it proved to be inefficient and pointless in practice. Our civil litigators simply cannot take the time to pursue civil cases against every individual employee who may be liable for misconduct, and we cannot afford to delay corporate resolutions because a bureaucratic rule suggests that companies need to continue investigating until they identify all involved employees and reach an agreement with the government about their roles.

    However, Yates still has force in the civil realm. Although the revised policy jettisons Yates’s “all or nothing” approach, it stakes out the type of disclosure required for minimum and maximum credit, with a pointed focus on senior management and the board of directors. To receive “any credit for cooperating in a civil case” under the revised policy, a company “must identify all wrongdoing by senior officials, including members of senior management or the board of directors.” At the other end of the spectrum, the revised civil policy echoes the criminal policy by providing for “maximum credit” only when a company “identif[ies] every individual person who was substantially involved in or responsible for the misconduct.”

    There is also a gray zone between the minimum- and maximum-credit boundaries, where a company can get “some credit” in exchange for “meaningful assistance.” In an example (that bears little relevance to the majority of FCA investigations), the deputy attorney general noted that “some credit” could be awarded where a company makes a “voluntary disclosure” but without “stipulating about which non-managerial employees are culpable).” Presumably, the deputy attorney general is not foreclosing the types of assistance that have been highlighted in other DOJ pronouncements, including as recently as June 2018 when then-Acting Associate Attorney General Jesse Panuccio detailed types of assistance that the DOJ regarded as significant in FCA matters, such as sharing results of an internal investigation, making witnesses available or identifying culpable individuals.

    However, it is clear that under the new policy, the DOJ can reward meaningful assistance without a company having to agree about every nonmanagerial employee with potential individual liability. In addition, the revised policy reaches back in the direction of the pre-Yates practice of granting releases for individuals. Yates eliminated the DOJ’s typical practice of granting releases to employees, officers and directors in corporate FCA settlements. Now, civil fraud attorneys are again “permitted to negotiate civil releases for individuals who do not warrant additional investigation in corporate civil settlement agreements, again with appropriate supervisory approval.” Whether the DOJ reverts to the prior broad releases as the new norm will be a key factor to monitor.

    In addition to these unanswered questions, there is the enduring mystery about what “credit” actually means in a practical, dollars-and-cents way. While most companies wish to cooperate with the government and can identify clear benefits, the Yates memo left practitioners scratching their heads regarding how the government actually quantifies “cooperation credit” in FCA matters. Credit and how it is calculated is well understood in criminal matters, but has not been a comfortable fit in the FCA arena.Notably, the only example the Yates memo gave on how cooperation credit might apply in a civil case related to the “reduced damages” provision of the FCA, 31 U.S.C. § 3729(a)(2), which already, as a statutory matter, provided for reduced damages where a party voluntarily discloses misconduct before knowledge of any investigation — the very small minority of FCA matters and an irrelevance to the vast majority of FCA settlements.

    In 2016, Baer spoke on what “credit” meant in FCA cases, but ultimately gave no more than an “assurance” that civil fraud attorneys would use their discretion to reward true cooperation in terms of the measure of damages, multipliers and penalties. Similarly, in June 2018, Panuccio explained that the DOJ has “tremendous enforcement discretion” with respect to FCA settlements and can provide a “material discount” based on cooperation. The deputy attorney general’s speech in November of this year also fails to put any meat on the bones of civil cooperation credit. Indeed, while the Justice Manual addresses credit in a civil context, it still fails to clarify what “maximum,” “minimum” or “some” cooperation credit means.[2]

    In October 2018, Director of Civil Frauds Michael Granston (a highly experienced, career DOJ attorney), announced at the HCCA Healthcare Enforcement Compliance Conference, that before year-end, civil frauds will be issuing written guidance to DOJ attorneys regarding: (a) the types of cooperation that qualify an FCA defendant for cooperation credit; and (b) the types of cooperation credit. Whether this augurs more specific guidance on cooperation credit in FCA cases is another open question, but such guidance would clearly be key to better understanding the benefits of cooperation in FCA matters.

    Authors
    More insights

  • International News: Life Sciences

    International News: Life Sciences

    INTERNATIONAL NEWS / REPORT

    International News: Life Sciences

    Winter 2018

    Read time: 2 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • ISS and Glass Lewis Update Proxy Voting Guidelines for 2019

    ISS and Glass Lewis Update Proxy Voting Guidelines for 2019

    ARTICLE / CLIENT ALERT

    ISS and Glass Lewis Update Proxy Voting Guidelines for 2019

    December 19, 2018

    Read time: 6 min

    Key takeaways
    Overview

    Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC both recently issued their annual proxy voting guideline updates. As revised, these guidelines have important implications for companies preparing for the 2019 proxy season.

    In depth

    ISS POLICY UPDATES

    BOARD GENDER DIVERSITY: Institutional Shareholder Services Inc. (ISS) announced that adverse voting recommendations may be issued against nominating committee chairs for boards without any female members. This new policy will be effective for meetings and nominations on or after February 1, 2020.

    DIRECTOR ATTENDANCE: In order to combat director absenteeism and chronic poor attendance, ISS will withhold recommendation from the chair of the nominating or governance committee after three years of poor attendance by a director. After four years of poor attendance, ISS will withhold recommendation from the full nominating or governance committee. If that director continues to have consistent poor attendance for five years or greater, ISS will withhold recommendation from the entire board.

    CONFLICTING PROPOSALS: There was a significant increase in 2018 of board-sponsored proposals to ratify existing charter or bylaw provisions in order to protect against having the company adopt more onerous shareholder-sponsored charter or bylaw proposals. ISS will withhold recommendation from individual directors, members of the governance committee, or even the full board in instances when boards ask shareholders to ratify any existing charter or bylaw provisions. The decision to withhold recommendation will be based on a variety of factors, including any competing shareholder proposal, the board’s rationale, previous disclosure efforts, the effect on shareholders and the company’s history.

    DIRECTOR PERFORMANCE: ISS will identify companies that have directors with long-term underperformance issues and boards with entrenchment-favoring policies. ISS changed the measurement of “sustained poor performance” based on total shareholder returns in the bottom half of a company’s industry group from a three-year interval to intervals of one, three and five years.

    REVERSE STOCK SPLITS: ISS updated its policy on reverse stock splits to codify the approach currently utilized by companies not listed on major exchanges and who are not proportionately reducing their authorized shares. ISS will recommend voting for reverse stock split proposals if the number of authorized shares is proportionately reduced or when the effective increase in authorized shares is equal to or less than the allowable increase. If the above conditions are not met, ISS will vote on a case-by-case basis based on the company’s disclosure, financial status and the rationale for the proposed reverse stock split.

    ENVIRONMENTAL AND SOCIAL: ISS has codified the existing factors it will use to analyze environmental and social shareholder proposals and indicated that significant controversies, fines, penalties or other litigation will also considered.

    GLASS LEWIS POLICY UPDATES

    BOARD GENDER DIVERSITY: Glass Lewis will recommend voting against nominating committee chairs of a board without a female member. For companies outside the Russell 3000 index or if the board provides sufficient rationale for not having any female board members, Glass Lewis may determine not to withhold its recommendation. This sufficient rationale includes timetables for addressing the lack of board gender diversity, notable governance and legal restrictions placed on the board, and any board agreements with investors. Glass Lewis will place special emphasis on companies headquartered in the state of California after the state passed a law that requires all California companies to have one woman on their board by the end of 2019, at least two women on boards of five members and at least three women on boards with six or more directors by 2021. Glass Lewis will recommend voting against any nominating committee chair of a California-based company unless there is adequate disclosure of compliance actions it will take to comply with the law.

    CONFLICTING PROPOSALS: Glass Lewis has codified its conflicting special meeting shareholder resolution policy, including the following:

    • If a company places on its proxy ballot both a management and shareholder proposal that request different thresholds for the right to call a special meeting, Glass Lewis will uniformly recommend voting for the lower threshold;
    • If there are conflicting management and shareholder special meeting proposals and the company does not maintain any special meeting rights, Glass Lewis will recommend that shareholders vote in favor of their own proposal or alternatively to abstain from voting on the management’s proposal; and
    • If companies exclude a special meeting shareholder proposal in favor of a management proposal ratifying any existing special meeting right, Glass Lewis will typically recommend against that ratification proposal and will also withhold recommending voting for the election of the nominating and governance committee.

    ENVIRONMENTAL AND SOCIAL: Glass Lewis will increasingly identify directors or committees charged with oversight of environmental and social material risks. Glass Lewis will provide investors notice of lack of board oversight and may also recommend that shareholders vote against members of the board’s audit committee based on these issues.

    VIRTUAL SHAREHOLDER MEETINGS: Glass Lewis provided a non-exclusive list of effective disclosure for virtual shareholder meetings. These include:

    • Addressing the ability of shareholders to ask questions during the meeting, time guidelines for questions, what types of questions are allowed and how to disclose questions to other participants;
    • Procedures for posting questions received during the meeting and the company’s answers on the investor page of its website after the meeting; and
    • Addressing technical and logistical issues and procedures.

    EXECUTIVE COMPENSATION: Glass Lewis has expanded its policies and guidelines relating to executive compensation including:

    • Recommending against voting for a member of the compensation committee when a new excise tax gross-up is provided in an executive employment agreement;
    • Requiring companies to provide shareholders with a meaningful explanation of any benefits agreed upon for severance arrangements;
    • Requiring companies to provide shareholders with a meaningful explanation of sign-on arrangements;
    • Increased scrutiny on large, front-loaded grants; and
    • For smaller reporting companies, recommending against voting for members of a company’s compensation committee if a reduction in executive compensation disclosure substantially impacts the shareholders’ ability to adequately assess the company’s executive compensation procedures.

    Conclusion

    A big takeaway from the 2019 ISS and Glass Lewis voting guideline updates is the focus on gender diversity on the board of directors. Following on similar measures published in recent years by large institutional shareholders and the new law passed in California, gender diversity is sure to be a hot topic on corporate boards in 2019.

    For additional information about McDermott’s Capital Markets and Public Company practice, please see our practice group page.

    Authors

    Adam K. Sherman

    Partner

    Chicago

    More insights

  • Free Parking Only Exists in Monopoly: New IRS Guidance Makes Employer-Provided Parking More Costly and Burdensome Than You Think

    Free Parking Only Exists in Monopoly: New IRS Guidance Makes Employer-Provided Parking More Costly and Burdensome Than You Think

    ARTICLE / CLIENT ALERT

    Free Parking Only Exists in Monopoly: New IRS Guidance Makes Employer-Provided Parking More Costly and Burdensome Than You Think

    December 18, 2018

    Read time: 6 min

    Key takeaways
    Overview

    As part of its comprehensive 2017 tax reform bill, Congress repealed deductions for Qualified Transportation Fringes including for employer-provided parking, while also requiring that tax-exempt organizations increase their unrelated business taxable income by the nondeductible parking expenses. Recently released IRS Notice 2018-99 addresses some of the year-end tax filing and tax planning concerns for affected employers with rules of special interest to tax-exempt employers.

    In depth

    In late 2017, Congress passed the Tax Cuts and Jobs Act, which included a repeal of the employer deduction for most “expenses” associated with providing qualified transportation fringe benefits (QTFs) and also required tax-exempt employers to increase their unrelated business taxable income (UBTI) by the amount of QTF expenses that would be nondeductible by a taxable employer. Without further guidance, both taxable and tax-exempt employers struggled to determine how this new provision would work. The Internal Revenue Service (IRS) released Notice 2018-99 (Notice) on December 10, 2018 to address some of these concerns.

    The Notice provides interim guidance on how to determine the amount of parking expenses that are nondeductible or must be added to UBTI until the IRS publishes proposed regulations addressing these issues. However, the interim guidance is a bit of a mixed bag, as it provides relief for “any reasonable method” for computing the deduction disallowance while at the same time expanding both the parking subject to the disallowance and the type of expenses that are disallowable. All employers, other than government employers (like the IRS), are subject to the guidance and should evaluate the resulting tax impact. Employers should also consider whether they want to take advantage of the provisions that allow for retroactive changes to parking policies in order to avoid some of the negative impacts of the guidance.

    Taxable Employers

    According to the Notice, an employer who owns or leases all or a portion of a parking facility for its employees may use “any reasonable method” to calculate the deduction disallowance until the IRS publishes proposed regulations. To provide certainty, the Notice includes a four-step safe harbor method that the IRS deems to be a reasonable method. The Notice also states that using the value of employee parking to determine parking expenses is not reasonable; therefore, the IRS position impacts an employer’s deduction even if the employer-provided parking has no, or a de minimis, fair market value.

    The safe harbor method takes into account both the number of reserved parking spaces for employees and the “total parking expense” attributable to the parking facility. Employers that provide reserved employee parking spots have until March 31, 2019 to change their parking arrangements, and any such changes will be deemed retroactive to January 1, 2018.

    While helpful, the four-step safe harbor method fails to address the most administratively burdensome step for employers: determining and allocating the underlying “total parking expenses.” This determination is critical because the total parking expense is applied against the ratio of employee parking (both reserved and nonreserved, if the lot is not primarily available for general public use) to determine the deduction disallowance.

    Under the Notice, parking expenses include, but are not limited to, repairs, maintenance, utility costs, insurance, property taxes, interest, snow and ice removal, leaf removal, trash removal, parking lot attendant expenses, security, and rent or lease payments. Most of these items are not separately broken out from the employer’s broader place of business property expenses, making it potentially burdensome and impractical to calculate. In addition to the administrative burden, the expansive interpretation of what constitutes “parking expenses” may have a disproportionately negative impact on employers that own parking lots and incur large continuing upkeep expenses (especially in areas where parking has no fair market value), as opposed to employers that pay a fixed amount to lease parking spots or have parking spots included as part of a larger lease.

    Importantly, the IRS did clarify that depreciation on a parking structure that is owned by an employer and used by the employer’s employees would not be considered a parking expense for purposes of the Notice.

    Tax-Exempt Employers

    Tax-exempt employers are not spared from this new burden. The methods for computing allocable parking costs mirror those governing taxable entities discussed above. Instead of a deduction disallowance, tax-exempt employers must increase their UBTI by the amount of the allocable “deduction disallowance.” The method used to track parking expenses outlined in the four-step safe harbor method may be particularly onerous for tax-exempt employers. This is because the administrative burden of tracking and allocating the expenses far outweighs the UBTI generated and can trigger a UBTI filing for tax-exempt entities that have never previously been subject to UBTI. Therefore, the guidance set forth in the Notice will have far-reaching effects unless the proposed regulations adopt more reasonable positions.

    Next Steps

    All nongovernmental employers should consider some important next steps.
    First, until the proposed regulations are released, taxable and tax-exempt employers should consult with their tax advisors regarding appropriate next steps to ascertain and adopt a reasonable method for calculating the disallowed deduction or increase in UBTI. Second, as solicited by the Notice, individual employers or associations should consider providing comments to the IRS (prior to February 22, 2019) seeking more easily administered rules (e.g., only allocate as parking expenses amounts that are separately broken out for parking, as opposed to the entire business premises); an exemption for parking with no, or a de minimis, fair market value; and clarification that the rules do not apply to reserved parking spaces for handicapped employees.
    Employers should also consider eliminating most, if not all, reserved parking, including spots reserved by places of worship for church staff or even spots reserved for employees as a reward on a rotating basis, such as for the “employee of the month.” Any changes should be made by March 31, 2019 to take advantage of the retroactive effect. Finally, employers should consider whether adopting an exemption for reserved parking for employees with special parking needs, such as handicapped parking, is a reasonable position under the Notice.

    Authors

    Robert C. Louthian , III

    Counsel

    Washington, DC

    More insights